

						acarix
		CAD	Scor <sup>®</sup> System	<b>Clinical Report</b>		
Patient Name:			Gender:			Date:
DOB:			CADScor Record ID	#:		Time Exam:
Patient ID #:			Insurance Company	:		Policy #:
CPT Code:						
<b>0716T</b> - Cardiac a	coustic waveform re	ecording with au	tomated analysis ar	nd generation of coro	nary arte	ry disease risk score.
ICD-Diagnosis co	des:					
Primary symptor	ns:		R07.82 Intercostal	pain		I10 Essential Hypertension
☐ I20.89 Other	forms of angina		R07.89 Other ches	t pain		condary Factors:
pectoris			R07.9 Chest pain,	unspecified	(Mu	st have primary symptom selected.)
☐ M79.601 Pai	n in right arm		R55 Syncope and o	collapse		E66.3 Overweight
☐ M79.602 Pai	n in left arm	Prin	nary Risk Factors:	·		E66.8 Other obesity
R06.00 Dysp	nea, unspecified		E10 Type 1	Diabetes		E83.52 Hypercalcemia
R06.02 Short	tness of breath		E11 Type 2	Diabetes		Z72.0 Tabacco Use
R06.89 Othe	r abnormalities of		E78.0 Pure Hypero	holesterolemia,		Z82.40 Family history of ischemic
breathing			unspecified			heart disease
R07.2 Precor	dial pain		E78.2 Mixed Hype	rlipidemia		Other:
CAD-score Exam	Result:			About CAD-score	risk group	:
The CAD-score is	s indicating risk of	having significar	nt	The CAD-score is a	patient s	pecific heart murmur score indicative
coronary artery o	lisease (CAD), define	ed as having <u>&gt;</u> 509	%	of Coronary Arter	y Disease	e (CAD)/Chronic Coronary Syndrome
luminal diameter	reduction.1			(CCS) for immed	diate risk	stratification, prior to potential
Two risk categori	es are defined using	the CADScor		secondary evaluat		
CADScor System:	=	•			below 20	indicates that your risk of significant
CAD-score:	≤ 20	> 20		CAD is low.	is in th	a alouated rick group, you may be
Risk Group:	Low Risk	Elevated Ri	sk	•		e elevated risk group, you may be ne or be referred onto secondary

## **Physician Clinical Assessment:**

Physician Signature:	Date:	
, ,	 	

## **SUMMARY**

- FDA Clearance: CADScor System is an FDA De Novo cleared class II device (DEN190047).
- 2. **Intended Use:** The intended use of CADScor System is to record heart sounds, murmurs and vibration, for calculation of a patient specific score, indicating the risk of coronary stenosis, as an aid in cardiac analysis and diagnosis.<sup>1</sup>

evaluation.

- 3. **Indications for Use:** The CADScor System is indicated for use as a diagnostic aid in symptomatic patients with suspected stable Coronary Artery Disease/Chronic Coronary Syndrome.<sup>1</sup>
- 4. **Clinical Data:** More than 6,000 patients studied in the CADScor System clinical program. Several clinical studies have been published demonstrating the efficiency of the CADScor System including two peer-reviewed published studies with independent patient populations (n=3,977) demonstrate that a CAD-score of 20 or less indicates no significant CAD, with a negative predictive value (NPV) reported between 95.4-97.2%.<sup>2,3</sup> The FDA labeling for the CADScor System is a NPV of 96.2%.<sup>1</sup>
- 5. **National Institute for Health and Care Excellence (NICE):** NICE MIB defines the CADScor System as a stable coronary artery disease rule-out method after first clinical evaluation (clinical history, physical examination, 12-lead ECG) and before CT coronary angiography (CTCA) (www.nice.org.uk/advice/mib174/chapter/summary).
- 6. Real-world Use: Worldwide use on 40,000 patients.
  - User manual US-FDA v.12.Y
  - Schmidt SE, Winther S, Larsen BS, et al. Coronary artery disease risk reclassification by a new acoustic-based score. Int J Cardiovasc Imaging. 2019;35(11):2019-2028. doi:10.1007/s10554019-01662-1 <a href="https://pubmed.ncbi.nlm.nih.gov/31273633/">https://pubmed.ncbi.nlm.nih.gov/31273633/</a>
  - 3. Rasmussen LD, Winther S, Karim SR, et al. Likelihood reclassification by an acoustic-based score in suspected coronary artery disease [published online ahead of print, 2023 Mar 16]. Heart. 2023;heartjnl-2023-322357. doi:10.1136/heartjnl-2023-322357 https://pubmed.ncbi.nlm.nih.gov/36878672/